View Item 

Show simple item record

Nutrition and Heart Failure: Impact of Drug Therapies and Management Strategies
dc.contributor.authorDunn, Steven P.
dc.contributor.authorBleske, Barry
dc.contributor.authorDorsch, Michael
dc.contributor.authorMacaulay, Tracy
dc.contributor.authorVan Tassell, Benjamin
dc.contributor.authorVardeny, Orly
dc.date.accessioned2018-02-05T16:47:17Z
dc.date.available2018-02-05T16:47:17Z
dc.date.issued2009-02
dc.identifier.citationDunn, Steven P.; Bleske, Barry; Dorsch, Michael; Macaulay, Tracy; Van Tassell, Benjamin; Vardeny, Orly (2009). "Nutrition and Heart Failure: Impact of Drug Therapies and Management Strategies." Nutrition in Clinical Practice 24(1): 60-75.
dc.identifier.issn0884-5336
dc.identifier.issn1941-2452
dc.identifier.urihttps://hdl.handle.net/2027.42/142156
dc.publisherSAGE Publications
dc.publisherWiley Periodicals, Inc.
dc.subject.otherdrug therapy
dc.subject.otherheart failure
dc.subject.othernutrition therapy
dc.subject.otherelectrolytes
dc.subject.othervitamins
dc.titleNutrition and Heart Failure: Impact of Drug Therapies and Management Strategies
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumUniversity of Michigan Health‐Systems and College of Pharmacy, Ann Arbor, Michigan,
dc.contributor.affiliationumUniversity of Michigan College of Pharmacy, Ann Arbor, Michigan,
dc.contributor.affiliationotherUniversity of Wisconsin–Madison School of Pharmacy, Madison, Wisconsin.
dc.contributor.affiliationotherUniversity of Utah College of Pharmacy, Salt Lake City, Utah, and
dc.contributor.affiliationotherUniversity of Kentucky Department of Pharmacy Services and College of Pharmacy, Lexington, Kentucky,
dc.contributor.affiliationotherDepartment of Pharmacy Services, University of Kentucky, Lexington, Kentucky,
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142156/1/ncp0060.pdf
dc.identifier.doi10.1177/0884533608329299
dc.identifier.sourceNutrition in Clinical Practice
dc.identifier.citedreferenceMak S, Newton GE. Vitamin C augments the inotropic response to dobutamine in humans with normal left ventricular function. Circulation. 2001; 103 ( 6 ): 826 – 830.
dc.identifier.citedreferenceBerman M, Erman A, Ben‐Gal T, et al. Coenzyme Q10 in patients with end‐stage heart failure awaiting cardiac transplantation: a randomized, placebo‐controlled study. Clin Cardiol. 2004; 27 ( 5 ): 295 – 299.
dc.identifier.citedreferenceMorisco C, Nappi A, Argenziano L, et al. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short‐term coenzyme Q10 treatment. Mol Aspects Med. 1994; 15 ( suppl ): S155 – S163.
dc.identifier.citedreferenceMunkholm H, Hansen HH, Rasmussen K. Coenzyme Q10 treatment in serious heart failure. Biofactors. 1999; 9 ( 2‐4 ): 285 – 289.
dc.identifier.citedreferenceSander S, Coleman CI, Patel AA, Kluger J, White CM. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail. 2006; 12 ( 6 ): 464 – 472.
dc.identifier.citedreferenceRundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 2004; 61 ( 6 ): 889 – 892.
dc.identifier.citedreferenceMortensen SA, Leth A, Agner E, Rohde M. Dose‐related decrease of serum coenzyme Q10 during treatment with HMG‐CoA reductase inhibitors. Mol Aspects Med. 1997; 18 ( suppl ): S137 – S144.
dc.identifier.citedreferencede Lorgeril M, Salen P. Selenium and antioxidant defenses as major mediators in the development of chronic heart failure. Heart Fail Rev. 2006; 11 ( 1 ): 13 – 17.
dc.identifier.citedreferenceNewman KP, Bhattacharya SK, Munir A, et al. Macro‐ and micronutrients in patients with congestive heart failure, particularly African‐Americans. Vasc Health Risk Manag. 2007; 3 ( 5 ): 743 – 747.
dc.identifier.citedreferenceYang GQ, Chen JS, Wen ZM, et al. The role of selenium in Keshan disease. Adv Nutr Res. 1984; 6: 203 – 231.
dc.identifier.citedreferenceQuercia RA, Korn S, O’Neill D, et al. Selenium deficiency and fatal cardiomyopathy in a patient receiving long‐term home parenteral nutrition. Clin Pharm. 1984; 3 ( 5 ): 531 – 535.
dc.identifier.citedreferenceSriram K, Peterson JK, O’Gara J, Hammond JM. Clinical improvement of congestive heart failure after selenium supplementation in total parenteral nutrition. Acta Pharmacol Toxicol (Copenh). 1986; 59 ( suppl 7 ): 361 – 364.
dc.identifier.citedreferenceCohen N, Golik A. Zinc balance and medications commonly used in the management of heart failure. Heart Fail Rev. 2006; 11 ( 1 ): 19 – 24.
dc.identifier.citedreferenceLi T, Singal PK. Adriamycin‐induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation. 2000; 102 ( 17 ): 2105 – 2110.
dc.identifier.citedreferenceKlevay LM. Cardiovascular disease from copper deficiency: a history. J Nutr. 2000; 130 ( 2S suppl ): 489S – 492S.
dc.identifier.citedreferenceAtlihan F, Soylemezoglu T, Gokce A, Guvendik G, Satici O. Zinc and copper in congestive heart failure. Turk J Pediatr. 1990; 32 ( 1 ): 33 – 38.
dc.identifier.citedreferenceKosar F, Sahin I, Taskapan C, et al. Trace element status (Se, Zn, Cu) in heart failure. Anadolu Kardiyol Derg. 2006; 6 ( 3 ): 216 – 220.
dc.identifier.citedreferenceOster O. Trace element concentrations (Cu, Zn, Fe) in sera from patients with dilated cardiomyopathy. Clin Chim Acta. 1993; 214 ( 2 ): 209 – 218.
dc.identifier.citedreferenceMalek F, Dvorak J, Jiresova E, Spacek R. Difference of baseline serum copper levels between groups of patients with different one year mortality and morbidity and chronic heart failure. Cent Eur J Public Health. 2003; 11 ( 4 ): 198 – 201.
dc.identifier.citedreferenceZick SM, Blume A, Aaronson KD. The prevalence and pattern of complementary and alternative supplement use in individuals with chronic heart failure. J Card Fail. 2005; 11 ( 8 ): 586 – 589.
dc.identifier.citedreferenceDavidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega‐3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8‐week, randomized, double‐blind, placebo‐controlled study. Clin Ther. 2007; 29 ( 7 ): 1354 – 1367.
dc.identifier.citedreferenceMcKenney JM, Sica D. Role of prescription omega‐3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy. 2007; 27 ( 5 ): 715 – 728.
dc.identifier.citedreferenceGISSI Heart Failure Investigators. Effect of n‐3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI‐HF trial): a randomised, double‐blind, placebo‐controlled trial. Lancet. 2008; 372 ( 9645 ): 1223 – 1230.
dc.identifier.citedreferenceKlepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm. 1999; 56 ( 2 ): 125 – 138, quiz 39‐41.
dc.identifier.citedreferenceHaller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000; 343 ( 25 ): 1833 – 1838.
dc.identifier.citedreferenceSamenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc. 2002; 77 ( 1 ): 12 – 16.
dc.identifier.citedreferenceWhite LM, Gardner SF, Gurley BJ, et al. Pharmacokinetics and cardiovascular effects of ma‐huang (Ephedra sinica) in normotensive adults. J Clin Pharmacol. 1997; 37 ( 2 ): 116 – 122.
dc.identifier.citedreferenceFood and Drug Administration. Sales of supplements containing ephedrine alkaloids (Ephedra) prohibited; 2004. Available at: http://www.fda.gov/oc/initiatives/ephedra/february2004/. Accessed July 13, 2008.
dc.identifier.citedreferenceHwang HS, Bleske BE, Ghannam MM, et al. Effects of hawthorn on cardiac remodeling and left ventricular dysfunction after 1 month of pressure overload‐induced cardiac hypertrophy in rats. Cardiovasc Drugs Ther. 2008; 22 ( 1 ): 19 – 28.
dc.identifier.citedreferenceTauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class‐III heart failure. Am Heart J. 2002; 143 ( 5 ): 910 – 915.
dc.identifier.citedreferenceAckman ML, Campbell JB, Buzak KA, et al. Use of nonprescription medications by patients with congestive heart failure. Ann Pharmacother. 1999; 33 ( 6 ): 674 – 679.
dc.identifier.citedreferencePage J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000; 160 ( 6 ): 777 – 784.
dc.identifier.citedreferenceRosamond W, Flegal K, Furie K, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008; 117 ( 4 ): e25 – e146.
dc.identifier.citedreferenceKenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002; 347 ( 5 ): 305 – 313.
dc.identifier.citedreferenceHunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure. J Am Coll Cardiol. 2005; 46 ( 6 ): e1 – e82.
dc.identifier.citedreferenceAnker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997; 349 ( 9058 ): 1050 – 1053.
dc.identifier.citedreferenceToth MJ, Gottlieb SS, Goran MI, Fisher ML, Poehlman ET. Daily energy expenditure in free‐living heart failure patients. Am J Physiol. 1997; 272 ( 3, pt 1 ): E469 – E475.
dc.identifier.citedreferencePoehlman ET. Special considerations in design of trials with elderly subjects: unexplained weight loss, body composition and energy expenditure. J Nutr. 1999; 129 ( 1S suppl ): 260S – 263S.
dc.identifier.citedreferenceRiley M, Elborn JS, McKane WR, et al. Resting energy expenditure in chronic cardiac failure. Clin Sci (Lond). 1991; 80 ( 6 ): 633 – 639.
dc.identifier.citedreferenceBerry C, Clark AL. Catabolism in chronic heart failure. Eur Heart J. 2000; 21 ( 7 ): 521 – 532.
dc.identifier.citedreferencePrice RJ, Witham MD, McMurdo ME. Defining the nutritional status and dietary intake of older heart failure patients. Eur J Cardiovasc Nurs. 2007; 6 ( 3 ): 178 – 183.
dc.identifier.citedreferenceSchwengel RH, Gottlieb SS, Fisher ML. Protein‐energy malnutrition in patients with ischemic and nonischemic dilated cardiomyopathy and congestive heart failure. Am J Cardiol. 1994; 73 ( 12 ): 908 – 910.
dc.identifier.citedreferenceCederholm T, Jagren C, Hellstrom K. Outcome of protein‐energy malnutrition in elderly medical patients. Am J Med. 1995; 98 ( 1 ): 67 – 74.
dc.identifier.citedreferenceBourdel‐Marchasson I, Emeriau JP. Nutritional strategy in the management of heart failure in adults. Am J Cardiovasc Drugs. 2001; 1 ( 5 ): 363 – 373.
dc.identifier.citedreferenceFrancis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med. 1984; 101 ( 3 ): 370 – 377.
dc.identifier.citedreferenceKrack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J. 2005; 26 ( 22 ): 2368 – 2374.
dc.identifier.citedreferenceTakala J. Determinants of splanchnic blood flow. Br J Anaesth. 1997; 77 ( 1 ): 50 – 58.
dc.identifier.citedreferenceFiddian‐Green RG, Baker S. Predictive value of the stomach wall pH for complications after cardiac operations: comparison with other monitoring. Crit Care Med. 1987; 15 ( 2 ): 153 – 156.
dc.identifier.citedreferenceSandek A, Bauditz J, Swidsinski A, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007; 50 ( 16 ): 1561 – 1569.
dc.identifier.citedreferenceAnker SD, Egerer KR, Volk HD, et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol. 1997; 79 ( 10 ): 1426 – 1430.
dc.identifier.citedreferenceAnker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin‐converting‐enzyme inhibitors: an observational study. Lancet. 2003; 361 ( 9363 ): 1077 – 1083.
dc.identifier.citedreferenceWitte KK, Clark AL. Nutritional abnormalities contributing to cachexia in chronic illness. Int J Cardiol. 2002; 85 ( 1 ): 23 – 31.
dc.identifier.citedreferenceBarrett‐Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986; 315 ( 24 ): 1519 – 1524.
dc.identifier.citedreferencePacker M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation. 1995; 92 ( 6 ): 1379 – 1382.
dc.identifier.citedreferenceWitte KK, Clark AL. Micronutrients and their supplementation in chronic cardiac failure: an update beyond theoretical perspectives. Heart Fail Rev. 2006; 11 ( 1 ): 65 – 74.
dc.identifier.citedreferenceKing D, Smith ML, Chapman TJ, Stockdale HR, Lye M. Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing. 1996; 25 ( 2 ): 144 – 149.
dc.identifier.citedreferenceKing D, Smith ML, Lye M. Gastro‐intestinal protein loss in elderly patients with cardiac cachexia. Age Ageing. 1996; 25 ( 3 ): 221 – 223.
dc.identifier.citedreferencevon Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res. 2007; 73 ( 2 ): 298 – 309.
dc.identifier.citedreferenceBerger MM, Mustafa I. Metabolic and nutritional support in acute cardiac failure. Curr Opin Clin Nutr Metab Care. 2003; 6 ( 2 ): 195 – 201.
dc.identifier.citedreferenceAnker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol. 2002; 85 ( 1 ): 51 – 66.
dc.identifier.citedreferenceCalle EE, Thun MJ, Petrelli JM, Rodriguez C, de CW Jr. Body‐mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999; 341 ( 15 ): 1097 – 1105.
dc.identifier.citedreferenceDiehr P, Bild DE, Harris TB, et al. Body mass index and mortality in nonsmoking older adults: the Cardiovascular Health Study. Am J Public Health. 1998; 88 ( 4 ): 623 – 629.
dc.identifier.citedreferencePeeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life‐table analysis. Ann Intern Med. 2003; 138 ( 1 ): 24 – 32.
dc.identifier.citedreferenceDunlap SH, Sueta CA, Tomasko L, de KF Jr. Association of body mass, gender and race with heart failure primarily due to hypertension. J Am Coll Cardiol. 1999; 34 ( 5 ): 1602 – 1608.
dc.identifier.citedreferenceChobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42 ( 6 ): 1206 – 1252.
dc.identifier.citedreferenceGrundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110 ( 2 ): 227 – 239.
dc.identifier.citedreferenceThird Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106 ( 25 ): 3143 – 3421.
dc.identifier.citedreferenceAnderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST‐elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST‐Elevation Myocardial Infarction: developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007; 116 ( 7 ): e148 – e304.
dc.identifier.citedreferenceLavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol. 2003; 91 ( 7 ): 891 – 894.
dc.identifier.citedreferenceDavos CH, Doehner W, Rauchhaus M, et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail. 2003; 9 ( 1 ): 29 – 35.
dc.identifier.citedreferenceHorwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001; 38 ( 3 ): 789 – 795.
dc.identifier.citedreferenceCurtis JP, Selter JG, Wang Y, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med. 2005; 165 ( 1 ): 55 – 61.
dc.identifier.citedreferenceAbbasi F, Brown BW Jr, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol. 2002; 40 ( 5 ): 937 – 943.
dc.identifier.citedreferenceBrunner EJ, Hemingway H, Walker BR, et al. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case‐control study. Circulation. 2002; 106 ( 21 ): 2659 – 2665.
dc.identifier.citedreferenceAdigun AQ, Ajayi AA. The effects of enalapril‐digoxin‐diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia. Eur J Heart Fail. 2001; 3 ( 3 ): 359 – 363.
dc.identifier.citedreferenceAnker SD, Coats AJ, Roecker EB, Scherhag A, Packer M. Does carvedilol prevent and reverse cardiac cachexia in patients with severe heart failure? Results from the COPERNICUS study. Eur Heart J. 2002; 23: 394.
dc.identifier.citedreferenceAnker SD, Lechat P, Dargie HJ. Prevention and reversal of cachexia in patients with chronic heart failure by bisoprolol: results from the CIBIS‐II study. J Am Coll Cardiol. 2003; 41: 156A – 157A.
dc.identifier.citedreferenceHryniewicz K, Androne AS, Hudaihed A, Katz SD. Partial reversal of cachexia by beta‐adrenergic receptor blocker therapy in patients with chronic heart failure. J Card Fail. 2003; 9 ( 6 ): 464 – 468.
dc.identifier.citedreferenceFlorea VG, Henein MY, Rauchhaus M, et al. The cardiac component of cardiac cachexia. Am Heart J. 2002; 144 ( 1 ): 45 – 50.
dc.identifier.citedreferenceMalkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: a double‐blind randomized placebo controlled trial. Eur Heart J. 2006; 27 ( 1 ): 57 – 64.
dc.identifier.citedreferencePugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J. 2003; 24 ( 10 ): 909 – 915.
dc.identifier.citedreferenceTritos NA, Danias PG. Growth hormone therapy in congestive heart failure due to left ventricular systolic dysfunction: a meta‐analysis. Endocr Pract. 2008; 14 ( 1 ): 40 – 49.
dc.identifier.citedreferenceArgiles JM, Lopez‐Soriano FJ, Busquets S. Novel approaches to the treatment of cachexia. Drug Discov Today. 2008; 13 ( 1‐2 ): 73 – 78.
dc.identifier.citedreferenceBruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer. 1990; 66 ( 6 ): 1279 – 1282.
dc.identifier.citedreferenceNeri B, Garosi VL, Intini C. Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: a multicentric cooperative study. Anticancer Drugs. 1997; 8 ( 5 ): 459 – 465.
dc.identifier.citedreferenceMcCarthy HD, Crowder RE, Dryden S, Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol. 1994; 265 ( 1‐2 ): 99 – 102.
dc.identifier.citedreferenceMantovani G, Maccio A, Esu S, et al. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer. 1997; 33 ( 4 ): 602 – 607.
dc.identifier.citedreferenceKalantar‐Zadeh K, Anker SD, Horwich TB, Fonarow GC. Nutritional and anti‐inflammatory interventions in chronic heart failure. Am J Cardiol. 2008; 101 ( 11A ): 89E – 103E.
dc.identifier.citedreferenceNagaya N, Kojima M, Kangawa K. Ghrelin, a novel growth hormone‐releasing peptide, in the treatment of cardiopulmonary‐associated cachexia. Intern Med. 2006; 45 ( 3 ): 127 – 134.
dc.identifier.citedreferenceIsgaard J, Bergh CH, Caidahl K, et al. A placebo‐controlled study of growth hormone in patients with congestive heart failure. Eur Heart J. 1998; 19 ( 11 ): 1704 – 1711.
dc.identifier.citedreferenceOsterziel KJ, Strohm O, Schuler J, et al. Randomised, double‐blind, placebo‐controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet. 1998; 351 ( 9111 ): 1233 – 1237.
dc.identifier.citedreferenceHenning R, Lundvall O. Evaluation in man of bumetanide, a new diuretic agent. Eur J Clin Pharmacol. 1973; 6 ( 4 ): 224 – 227.
dc.identifier.citedreferenceJayakumar S, Puschett JB. Study of the sites and mechanisms of action of bumetanide in man. J Pharmacol Exp Ther. 1977; 201 ( 1 ): 251 – 258.
dc.identifier.citedreferenceBranch RA, Read PR, Levine D, et al. Furosemide and bumetanide: a study of responses in normal English and German subjects. Clin Pharmacol Ther. 1976; 19 ( 5 pt 1 ): 538 – 545.
dc.identifier.citedreferenceAhmed A, Zannad F, Love TE, et al. A propensity‐matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J. 2007; 28 ( 11 ): 1334 – 1343.
dc.identifier.citedreferenceCleland JG, Dargie HJ, Ford I. Mortality in heart failure: clinical variables of prognostic value. Br Heart J. 1987; 58 ( 6 ): 572 – 582.
dc.identifier.citedreferenceHolland OB, Nixon JV, Kuhnert L. Diuretic‐induced ventricular ectopic activity. Am J Med. 1981; 70 ( 4 ): 762 – 768.
dc.identifier.citedreferenceCeremuzynski L, Gebalska J, Wolk R, Makowska E. Hypomagnesemia in heart failure with ventricular arrhythmias: beneficial effects of magnesium supplementation. J Intern Med. 2000; 247 ( 1 ): 78 – 86.
dc.identifier.citedreferenceOladapo OO, Falase AO. Congestive heart failure and ventricular arrhythmias in relation to serum magnesium. Afr J Med Med Sci. 2000; 29 ( 3‐4 ): 265 – 268.
dc.identifier.citedreferenceSwaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev. 2003; 24 ( 2 ): 47 – 66.
dc.identifier.citedreferenceNorris W, Kunzelman KS, Bussell S, Rohweder L, Cochran RP. Potassium supplementation, diet vs pills: a randomized trial in postoperative cardiac surgery patients. Chest. 2004; 125 ( 2 ): 404 – 409.
dc.identifier.citedreferenceMann JF, Yi QL, Sleight P, et al. Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study. Clin Nephrol. 2005; 63 ( 3 ): 181 – 187.
dc.identifier.citedreferenceD’Costa DF, Basu SK, Gunasekera NP. ACE inhibitors and diuretics causing hypokalaemia. Br J Clin Pract. 1990; 44 ( 1 ): 26 – 27.
dc.identifier.citedreferencePacker M, Lee WH. Provocation of hyper‐ and hypokalemic sudden death during treatment with and withdrawal of converting‐enzyme inhibition in severe chronic congestive heart failure. Am J Cardiol. 1986; 57 ( 4 ): 347 – 348.
dc.identifier.citedreferenceGriffing GT, Sindler BH, Aurecchia SA, Melby JC. Reversal of diuretic‐induced secondary hyperaldosteronism and hypokalemia by enalapril (MK‐421): a new angiotensin‐converting enzyme inhibitor. Metabolism. 1983; 32 ( 7 ): 711 – 716.
dc.identifier.citedreferencePacker M, Poole‐Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin‐converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999; 100 ( 23 ): 2312 – 2318.
dc.identifier.citedreferenceSaito M, Takada M, Hirooka K, Isobe F, Yasumura Y. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. J Clin Pharm Ther. 2005; 30 ( 6 ): 603 – 610.
dc.identifier.citedreferenceJuurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351 ( 6 ): 543 – 551.
dc.identifier.citedreferenceRosenberg J, Gustafsson F, Galatius S, Hildebrandt PR. Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther. 2005; 19 ( 4 ): 301 – 306.
dc.identifier.citedreferenceTanphaichitr V. Thiamin. In: Shils M, Olson J, Shike M, Ross A, eds. Modern Nutrition in Health and Disease. 9th ed. Baltimore, MD: Williams & Wilkins; 1999: 381 – 389.
dc.identifier.citedreferenceSica DA. Loop diuretic therapy, thiamine balance, and heart failure. Congest Heart Fail. 2007; 13 ( 4 ): 244 – 247.
dc.identifier.citedreferenceWilkinson TJ, Hanger HC, George PM, Sainsbury R. Is thiamine deficiency in elderly people related to age or co‐morbidity? Age Ageing. 2000; 29 ( 2 ): 111 – 116.
dc.identifier.citedreferenceSuter PM, Haller J, Hany A, Vetter W. Diuretic use: a risk for subclinical thiamine deficiency in elderly patients. J Nutr Health Aging. 2000; 4 ( 2 ): 69 – 71.
dc.identifier.citedreferenceZenuk C, Healey J, Donnelly J, et al. Thiamine deficiency in congestive heart failure patients receiving long term furosemide therapy. Can J Clin Pharmacol. 2003; 10 ( 4 ): 184 – 188.
dc.identifier.citedreferenceSuter PM. Forgotten metabolic side effects of diuretics: lipids, glucose and vitamin B1 (thiamin) metabolism [in French, German]. Schweiz Rundsch Med Prax. 2004; 93 ( 20 ): 857 – 863.
dc.identifier.citedreferenceRieck J, Halkin H, Almog S, et al. Urinary loss of thiamine is increased by low doses of furosemide in healthy volunteers. J Lab Clin Med. 1999; 134 ( 3 ): 238 – 243.
dc.identifier.citedreferenceSeligmann H, Halkin H, Rauchfleisch S, et al. Thiamine deficiency in patients with congestive heart failure receiving long‐term furosemide therapy: a pilot study. Am J Med. 1991; 91 ( 2 ): 151 – 155.
dc.identifier.citedreferenceShimon I, Almog S, Vered Z, et al. Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long‐term furosemide therapy. Am J Med. 1995; 98 ( 5 ): 485 – 490.
dc.identifier.citedreferenceSmithline HA. Thiamine for the treatment of acute decompensated heart failure. Am J Emerg Med. 2007; 25 ( 1 ): 124 – 126.
dc.identifier.citedreferenceEffect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med. 1992; 327 ( 10 ): 685 – 691.
dc.identifier.citedreferenceCohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine‐isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991; 325 ( 5 ): 303 – 310.
dc.identifier.citedreferencePitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341 ( 10 ): 709 – 717.
dc.identifier.citedreferencePitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post‐AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001; 15 ( 1 ): 79 – 87.
dc.identifier.citedreferencePfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM‐Overall programme. Lancet. 2003; 362 ( 9386 ): 759 – 766.
dc.identifier.citedreferenceKoren‐Michowitz M, Dishy V, Zaidenstein R, et al. The effect of losartan and losartan/hydrochlorothiazide fixed‐combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open‐label study. Am J Hypertens. 2005; 18 ( 3 ): 358 – 363.
dc.identifier.citedreferenceZumkley H, Bertram HP, Vetter H, Zidek W, Losse H. Zinc metabolism during captopril treatment. Horm Metab Res. 1985; 17 ( 5 ): 256 – 258.
dc.identifier.citedreferenceAbu‐Hamdan DK, Desai H, Sondheimer J, et al. Taste acuity and zinc metabolism in captopril‐treated hypertensive male patients. Am J Hypertens. 1988; 1 ( 3 pt 3 ): 303S – 308S.
dc.identifier.citedreferenceBakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL‐K Study Group. Kidney Int. 2000; 58 ( 5 ): 2084 – 2092.
dc.identifier.citedreferenceEffects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987; 316 ( 23 ): 1429 – 1435.
dc.identifier.citedreferenceCohn JN, Tognoni G. A randomized trial of the angiotensin‐receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345 ( 23 ): 1667 – 1675.
dc.identifier.citedreferenceDesai AS, Swedberg K, McMurray JJ, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol. 2007; 50 ( 20 ): 1959 – 1966.
dc.identifier.citedreferencePhillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse effects of combination angiotensin II receptor blockers plus angiotensin‐converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med. 2007; 167 ( 18 ): 1930 – 1936.
dc.identifier.citedreferenceSchoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001; 104 ( 16 ): 1985 – 1991.
dc.identifier.citedreferenceClausen T, Flatman JA. Beta 2‐adrenoceptors mediate the stimulating effect of adrenaline on active electrogenic Na‐K‐transport in rat soleus muscle. Br J Pharmacol. 1980; 68 ( 4 ): 749 – 755.
dc.identifier.citedreferenceShah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol. 2005; 46 ( 5 ): 845 – 849.
dc.identifier.citedreferenceSaito M, Nakayama D, Takada M, Hirooka K, Yasumura Y. Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil. J Clin Pharm Ther. 2006; 31 ( 6 ): 535 – 540.
dc.identifier.citedreferenceAllard ML, Jeejeebhoy KN, Sole MJ. The management of conditioned nutritional requirements in heart failure. Heart Fail Rev. 2006; 11 ( 1 ): 75 – 82.
dc.identifier.citedreferenceCarlton‐Conway D, Tulloh R, Wood L, Kanabar D. Vitamin D deficiency and cardiac failure in infancy. J R Soc Med. 2004; 97 ( 5 ): 238 – 239.
dc.identifier.citedreferenceLaguardia SP, Dockery BK, Bhattacharya SK, et al. Secondary hyperparathyroidism and hypovitaminosis D in African‐Americans with decompensated heart failure. Am J Med Sci. 2006; 332 ( 3 ): 112 – 118.
dc.identifier.citedreferenceMaiya S, Sullivan I, Allgrove J, et al. Hypocalcaemia and vitamin D deficiency: an important, but preventable, cause of life‐threatening infant heart failure. Heart. 2008; 94 ( 5 ): 581 – 584.
dc.identifier.citedreferenceJahn H, Schohn D, Omichi A, Miller R. Effects of 1,25(OH)2D3 on cardiovascular function. Contrib Nephrol. 1991; 90: 79 – 87.
dc.identifier.citedreferenceFriedman PA, Bushinsky DA. Diuretic effects on calcium metabolism. Semin Nephrol. 1999; 19 ( 6 ): 551 – 556.
dc.identifier.citedreferenceBurgess ED, Hawkins RG, Watanabe M. Interaction of 1,25‐dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am J Hypertens. 1990; 3 ( 12 pt 1 ): 903 – 905.
dc.identifier.citedreferenceKimura Y, Kawamura M, Owada M, et al. Effectiveness of 1,25‐dihydroxyvitamin D supplementation on blood pressure reduction in a pseudohypoparathyroidism patient with high renin activity. Intern Med. 1999; 38 ( 1 ): 31 – 35.
dc.identifier.citedreferenceSchleithoff SS, Zittermann A, Tenderich G, et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double‐blind, randomized, placebo‐controlled trial. Am J Clin Nutr. 2006; 83 ( 4 ): 754 – 759.
dc.identifier.citedreferenceKambara H, Itfeld BJ, Phillips J. Hypocalcemia and intractable ventricular fibrillation. Ann Intern Med. 1977; 86 ( 5 ): 583 – 584.
dc.identifier.citedreferenceBrunvand L, Haga P, Tangsrud SE, Haug E. Congestive heart failure caused by vitamin D deficiency? Acta Paediatr. 1995; 84 ( 1 ): 106 – 108.
dc.identifier.citedreferenceRimailho A, Bouchard P, Schaison G, Richard C, Auzepy P. Improvement of hypocalcemic cardiomyopathy by correction of serum calcium level. Am Heart J. 1985; 109 ( 3, pt 1 ): 611 – 613.
dc.identifier.citedreferenceShane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997; 103 ( 3 ): 197 – 207.
dc.identifier.citedreferenceWitte KK, Nikitin NP, Parker AC, et al. The effect of micronutrient supplementation on quality‐of‐life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J. 2005; 26 ( 21 ): 2238 – 2244.
dc.identifier.citedreferenceVermeulen EG, Stehouwer CD, Twisk JW, et al. Effect of homocysteine‐lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo‐controlled trial. Lancet. 2000; 355 ( 9203 ): 517 – 522.
dc.identifier.citedreferenceBonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006; 354 ( 15 ): 1578 – 1588.
dc.identifier.citedreferenceLonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006; 354 ( 15 ): 1567 – 1577.
dc.identifier.citedreferenceShinke T, Shite J, Takaoka H, et al. Vitamin C restores the contractile response to dobutamine and improves myocardial efficiency in patients with heart failure after anterior myocardial infarction. Am Heart J. 2007; 154 ( 4 ): 645, e1 – e8.
dc.identifier.citedreferenceBjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta‐analysis. JAMA. 2007; 297 ( 8 ): 842 – 857.
dc.identifier.citedreferenceCook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women’s Antioxidant Cardiovascular Study. Arch Intern Med. 2007; 167 ( 15 ): 1610 – 1618.
dc.identifier.citedreferenceLonn E, Bosch J, Yusuf S, et al. Effects of long‐term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005; 293 ( 11 ): 1338 – 1347.
dc.identifier.citedreferenceMarchioli R, Levantesi G, Macchia A, et al. Vitamin E increases the risk of developing heart failure after myocardial infarction: results from the GISSI‐Prevenzione trial. J Cardiovasc Med (Hagerstown). 2006; 7 ( 5 ): 347 – 350.
dc.identifier.citedreferenceBowry VW, Ingold KU, Stocker R. Vitamin E in human low‐density lipoprotein: when and how this antioxidant becomes a pro‐oxidant. Biochem J. 1992; 288 ( pt 2 ): 341 – 344.
dc.identifier.citedreferenceMortensen SA, Vadhanavikit S, Muratsu K, Folkers K. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tissue React. 1990; 12 ( 3 ): 155 – 162.
dc.identifier.citedreferenceHofman‐Bang C, Rehnqvist N, Swedberg K, Wiklund I, Astrom H. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure: the Q10 Study Group. J Card Fail. 1995; 1 ( 2 ): 101 – 107.
dc.identifier.citedreferenceKhatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. 2000; 132 ( 8 ): 636 – 640.
dc.identifier.citedreferenceMorisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long‐term multicenter randomized study. Clin Investig. 1993; 71 ( 8 suppl ): S134 – S136.
dc.identifier.citedreferencePermanetter B, Rossy W, Klein G, et al. Ubiquinone (coenzyme Q10) in the long‐term treatment of idiopathic dilated cardiomyopathy. Eur Heart J. 1992; 13 ( 11 ): 1528 – 1533.
dc.identifier.citedreferenceWatson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol. 1999; 33 ( 6 ): 1549 – 1552.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ncp0060.pdf
Size:
126.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.